炭疽病治疗的一剂良方瑞西巴库

发布时间：2018-10-16 21:54

【摘要】：炭疽病是由炭疽杆菌引起的一种高传染性和致死率的疾病。炭疽毒素抗体治疗能有效降低炭疽病的发病率和死亡率,已成为炭疽病治疗的重要疗法之一。瑞西巴库是第一个获批的单克隆抗毒素抗体,对于疑似感染者,可同时注射瑞西巴库和炭疽疫苗以加强免疫。对于吸入性炭疽病,可与其他相关抗生素一起用于治疗炭疽病。瑞西巴库通过阻止炭疽毒素保护性抗原元件与宿主中相应受体结合的方式,防止毒素对宿主造成伤害。临床试验表明该药使用安全,动物实验证实该药在治疗与预防吸入性炭疽方面颇为有效。本文对炭疽病的病理生理特征和瑞西巴库的作用机制、疗效以及注意事项作简要概述。
[Abstract]:Anthrax is a highly infectious and fatal disease caused by Bacillus anthracis. Anthrax toxin antibody therapy can effectively reduce the incidence and mortality of anthrax, and has become one of the important treatments for anthrax. Rexibacu is the first approved monoclonal anti-toxin antibody, and for suspected patients, both Rexibacu and anthrax vaccines can be injected to enhance immunization. For inhaled anthracnose, it can be used with other antibiotics to treat anthracnose. By preventing anthrax toxin protective antigen elements from binding to the corresponding receptors in the host, Rexibacu prevents the toxin from harming the host. Clinical trials showed that the drug was safe to use, and animal experiments showed that it was effective in the treatment and prevention of inhaled anthrax. The pathophysiological characteristics of anthracnose and the mechanism, curative effect and attention of Rexi Baku are briefly summarized in this paper.
【作者单位】：军事医学科学院放射与辐射医学研究所;
【基金】：国家“重大新药创制”科技重大专项(2012ZX09301003-001-007);国家“重大新药创制”科技重大专项(2015ZX09501007);国家“重大新药创制”科技重大专项(2015ZX09501008) 上海市科技支撑项目(13431901000)
【分类号】：R517.2

【参考文献】